RetinaLyze International

RetinaLyze International Safe, fast and efficient retinal investigations with RetinaLyze AI and Telemedicine. Retinalyze is based on the vision to prevent loss of eyesight.

Worldwide diabetes is an increasing problem and +300 million registered diabetics (type 1 or 2) are expected in 2020. Furthermore by 2020 +250 million unregistered diabetics are expected. One of the most feared consequences of diabetes is retinal diabetic pathology since this can lead to blindness. Early diagnosis is crucial – and possible with Retinalyze. A good diabetic plan and a non-complicated laser treatment can prevent loss of sight and blindness. Our mission is to make it easier for people all over the world to have their eyes tested and prevent the tragic consequences caused by late treatment of retinal lesions. Retinalyze System A/S is a registered company in Denmark.

As part of the expanding Heidelberg Engineering AppWay ecosystem, we’re thrilled to showcase how RetinaLyze® helps eye c...
11/11/2025

As part of the expanding Heidelberg Engineering AppWay ecosystem, we’re thrilled to showcase how RetinaLyze® helps eye care professionals detect signs of pathology such as diabetic retinopathy, AMD, and glaucoma.

Join Teddy Birch Petersen (CEO & Owner) and Ganesh Ram (CCO & Founder) from RetinaLyze System A/S as they present:

Webinar: "RetinaLyze – AI-Powered Eye Screening"
Date: Wednesday, 26 November 2025
Time: 1:00–2:00 PM CET

Learn how RetinaLyze, our CE-certified, AI-powered eye screening software, provides instant, reproducible analyses of fundus images helping clinics save time, standardize care, and prevent avoidable vision loss.

We look forward to connecting with the community of optometrists, ophthalmologists, and eye care innovators joining this session!

👉 Register via Heidelberg Engineering’s official channels, or directly via this link: https://go.heidelbergengineering.com/l/187512/2025-10-27/4237g9r

04/11/2025

Every day, optometrists and ophthalmologists work on the frontlines of vision health.

Detecting diseases that often show no early symptoms but can lead to lifelong blindness if missed.

At RetinaLyze, we believe technology should empower these professionals. Not replace them.

Our mission is simple: to make early detection of retinal diseases accessible, fast, and reliable.

Using AI-based image analysis, RetinaLyze helps eye care professionals:
Detect signs of eye diseases such as diabetic retinopathy, AMD, and glaucoma in seconds.

Integrate screening directly into their daily workflow. No complex setup or hardware changes needed.

Collaborate with specialists remotely, ensuring every patient can access the right care at the right time.

For over a decade, RetinaLyze has supported optometrists, ophthalmologists, and healthcare chains worldwide. We've screened millions of patients, preventing avoidable vision loss.

But what truly sets us apart is not just the AI.

It’s the combination of clinical validation, telemedicine workflow, and human collaboration that ensures every result leads to meaningful action.

Because in the end, technology doesn’t save sight. People who care about eyecare do.

Proud moment for us all at RetinaLyze System A/S! ✨A new study supporting the use of RetinaLyze Glaucoma is now publishe...
29/10/2025

Proud moment for us all at RetinaLyze System A/S! ✨

A new study supporting the use of RetinaLyze Glaucoma is now published in one of the most the prestigious publications in the world: Scientific Reports.

𝐖𝐡𝐚𝐭 𝐰𝐚𝐬 𝐬𝐭𝐮𝐝𝐢𝐞𝐝
Design: Cross-sectional analysis of 89 eyes from 57 glaucoma patients.
Imaging & tests: Standard color fundus photos analyzed with automated colorimetry (RetinaLyze Glaucoma known as Laguna ONhE in research), plus OCT/OCTA and visual fields (Octopus 900).

What RetinaLyze Glaucoma measures: Optic nerve head hemoglobin (ONH Hb) distribution across 24 sectors, yielding indices such as GDF and GIP that relate to cup/rim morphology and cup-to-disc ratio.

𝐊𝐞𝐲 𝐭𝐚𝐤𝐞𝐚𝐰𝐚𝐲𝐬
ONH Hb tracks damage: RetinaLyze Glaucoma indices correlated significantly with RNFL and GCL thickness and with visual-field metrics. This supports ONH Hb as a practical, non-invasive marker of structural/functional loss in glaucoma.

Speed + cost matter: For large-scale screening, methods that are fast and cost-effective enable broader coverage; RetinaLyze Glaucoma uses a standard fundus camera and delivers quantitative, repeatable outputs.

Monitoring over time: The software quantifies cup/rim and sectoral Hb patterns, helping flag subtle changes near the edge of normality and compare images across follow-up.

𝐖𝐡𝐲 𝐢𝐭 𝐦𝐚𝐭𝐭𝐞𝐫𝐬
Vascular factors play a major role in glaucoma. Evaluating ONH Hb offers an accessible window into perfusion-linked structural damage and complements OCT/OCTA where cost, availability, or anatomy are limiting.

Link to the paper in the comments!

Thanks and congratulations to the author team: Gustavo Caiado, Gustavo Samico, Gilvan V. da Silva Filho, sergio teixeira, Tiago Prata, Carolina Pelegrini Barbosa Gracitelli, Augusto Paranhos and to collaborators and technology partners who make this work possible.

AI in eye care only works when trust, workflow and patient connection come first.This recent piece by Dr. Scot Morris, O...
27/10/2025

AI in eye care only works when trust, workflow and patient connection come first.

This recent piece by Dr. Scot Morris, OD lays out the real hurdles: clinician trust (the “black box” problem), implementation cost and complexity, and patient concerns about losing the human touch.

These are exactly the challenges we’ve designed RetinaLyze to address.

How we approach it at RetinaLyze:
- Clinician-first transparency with clear results and visual cues so decisions are explainable.
- Fits your workflow with simple deployment, training and support that help teams adopt AI without disrupting patient flow.
- Augments, not replaces eye care professionals. AI flags risk, optometrists and ophthalmologists make the call. The patient relationship stays at the center.

If you’re an ECP, clinic leader or distributor exploring AI-enabled screening and telemedicine pathways, let’s talk about pragmatic steps to build trust, efficiency and access.

👉 Read the conversation starter from AI in Eye Care and Dr. Scot Morris, OD: https://aiineyecare.com/what-hurdles-must-ai-clear/

Congratulations to the Danish-LATAM Health Alliance - the team at The Trade Council of Denmark in Latin America, the mem...
22/10/2025

Congratulations to the Danish-LATAM Health Alliance - the team at The Trade Council of Denmark in Latin America, the members and participants in the first events! 👏 💯

At yesterdays event on PPP (Private Public Partnerships) RetinaLyze had the honour to share experiences on how to create positive outcomes for patients and parties involved. We presented for healthcare stakeholders from Brazil, Mexico, Chile, Columbia and Costa Rica alongside brilliant speakers with impressive presentations. It was a true pleasure to listen and learn from you Maria Kristiansen, Lars Hulbaek, Jens-Christian Holm, Julia Abrams, Simon Madsen, Patricia Byington and others joining! Thanks! 🙌 🥳

Well done and kudos to Tina Gottlieb, Laura Caroline Leme Bonani, Danilo Guimarães, Carlos Manuel Castillo Vázquez, Magnus Teis Rasmussen Wøhler, Benjamin Thokwa Brown, Anne Mette Vega Brondbjerg, Rebeca de Carvalho Ferreira and acosta! 🙌
You succeed with bringing the purpose to live: Sharing knowledge and best practices across the countries, exploring innovative healthcare and digital solutions, support building partnerships that target multi-stakeholder solutions in prevention, care, and rehabilitation and paving the way for sustainable solutions for healthier and more empowered ageing populations. 🙏

Good clinical records is your best insurance!We’ve turned key takeaways on good clinical record keeping into a quick, pr...
22/10/2025

Good clinical records is your best insurance!

We’ve turned key takeaways on good clinical record keeping into a quick, practical guide for optometrists.

Based on advice from Henrik Holton, Expert at Styrelsen for Patientklager and optometrist at Synscentralen i Vordingborg (Denmark).

This general guidance follows Danish standards. Always check local regulations in your country/region.

Read the full guide 👉 www.retinalyze.com/post/good-clinical-record-keeping-for-optometrists-a-practical-guide

Wow! I (Teddy) just dropped by our customer Cornelius K in Denmark.What a pleasure to step into such a beautifully cura...
20/10/2025

Wow! I (Teddy) just dropped by our customer Cornelius K in Denmark.

What a pleasure to step into such a beautifully curated store. The space reflects owners Annette Thue Holmstrøm and Daniel Back and their team’s commitment to going the extra mile to create outstanding experiences for every customer.

Many thanks to Daniel for the positive feedback on your use of RetinaLyze AI.

It was lovely to say a quick hello! Customers in the store rightly come first. Thank you!

NAION is now listed as a very rare side effect with semaglutide (Ozempic, Wegovy, Rybelsus)!The European Medicines Agenc...
15/10/2025

NAION is now listed as a very rare side effect with semaglutide (Ozempic, Wegovy, Rybelsus)!

The European Medicines Agency has confirmed that non-arteritic anterior ischemic optic neuropathy (NAION) is a very rare side effect of semaglutide-based medicines and has updated EU product information accordingly (“very rare” =

09/10/2025

We love for World Sight Day 💙

At RetinaLyze, we’re proud supporters of the International Agency for the Prevention of Blindness (IAPB) and their Love Your Eyes campaign. Making advanced eye care more accessible is why we exist! It only works when the whole ecosystem leans in.

Together with our customers, we’ve completed 6,000,000+ eye screenings.

Bringing timely, AI-assisted detection closer to patients and freeing up specialists to focus on treatment. That’s millions of opportunities to prevent avoidable vision loss.

Thank you to the optometrists, ophthalmologists, nurses, technicians, clinic managers, and our distributor partners who make this impact possible every day.

Let’s keep momentum:
- Encourage a friend or patient to get screened
- Share the Love Your Eyes message in your community
- Explore how AI-assisted screening can expand access in your setting

Grateful for this early customer feedback from the Netherlands 🇳🇱We’re happy to share a first review of RetinaLyze® from...
06/10/2025

Grateful for this early customer feedback from the Netherlands 🇳🇱

We’re happy to share a first review of RetinaLyze® from Boudewijn at van Warmerdam Opticiens:

“Our experience with RetinaLyze® is positive. The system enables us to detect eye abnormalities quickly and accurately, which saves us valuable time in the practice. The user-friendly interface makes it easy to review analyses and share them with patients. Thanks to the fast feedback, we can raise our quality of care and spot eye diseases earlier.”

A big thank you to Boudewijn Joppe and the team at van Warmerdam Opticiens, and to our partner EyeVinci B.V. for bringing AI-assisted screening closer to everyday eye care. Early reviews like this confirm what we experience across clinics and optical stores: smart technology, when made simple, truly makes a difference.

Curious what RetinaLyze System A/S could do in your practice or optical store in the Netherlands?

Contact : 088-600 8700 · info@eyevinci.nl

Adresse

Mileparken 10C
Skovlunde
2740

Åbningstider

Mandag 09:00 - 17:30
Tirsdag 09:00 - 17:30
Onsdag 09:00 - 17:30
Torsdag 09:00 - 17:30
Fredag 09:00 - 17:30

Internet side

Underretninger

Vær den første til at vide, og lad os sende dig en email, når RetinaLyze International sender nyheder og tilbud. Din e-mail-adresse vil ikke blive brugt til andre formål, og du kan til enhver tid afmelde dig.

Kontakt Praksis

Send en besked til RetinaLyze International:

Genveje

Del

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Prevention of blindness through AI

RetinaLyze prevents loss of eyesight by making eye screening accessible. 80% of all blindness is preventable. Early screening and diagnosis is crucial and possible with Retinalyze'​ automated retinal screening tools and telemedicine solutions. Our mission is to make it easier for people all over the world to have their eyes tested and prevent the tragic consequences caused by late treatment of retinal lesions.

RetinaLyze® is a screening software, which helps eye care professionals perform screenings for eye diseases in a safe and efficient manner. The automated algorithm (AI) module detects eye diseases by analyzing fundus images. It can be used as a clinical decision support system (CDSS) or as a screening tool in conjunction with the telemedicine module. Retinalyze System A/S is a registered company in Denmark. Check us out at https://RetinaLyze.com.